Immunocore Holdings Past Earnings Performance
Past criteria checks 0/6
Immunocore Holdings has been growing earnings at an average annual rate of 20.4%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 51.1% per year.
Key information
20.4%
Earnings growth rate
58.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 51.1% |
| Return on equity | -12.5% |
| Net Margin | -15.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Immunocore Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 296 | -47 | 155 | 1 |
| 30 Jun 24 | 281 | -55 | 155 | 0 |
| 31 Mar 24 | 265 | -60 | 151 | 0 |
| 31 Dec 23 | 249 | -55 | 144 | 0 |
| 30 Sep 23 | 237 | -69 | 164 | 5 |
| 30 Jun 23 | 220 | -61 | 141 | 0 |
| 31 Mar 23 | 201 | -52 | 131 | 0 |
| 31 Dec 22 | 174 | -53 | 123 | 0 |
| 30 Sep 22 | 114 | -62 | 84 | 0 |
| 30 Jun 22 | 82 | -112 | 101 | 0 |
| 31 Mar 22 | 53 | -156 | 116 | 0 |
| 31 Dec 21 | 36 | -180 | 111 | 0 |
| 30 Sep 21 | 37 | -150 | 105 | -78 |
| 30 Jun 21 | 39 | -139 | 94 | -51 |
| 31 Mar 21 | 42 | -116 | 78 | 0 |
| 31 Dec 20 | 41 | -101 | 63 | 0 |
| 30 Sep 20 | 37 | -105 | 52 | 106 |
| 30 Jun 20 | 34 | -109 | 55 | 102 |
| 31 Mar 20 | 33 | -120 | 53 | 90 |
| 31 Dec 19 | 34 | -138 | 59 | 0 |
| 31 Dec 18 | 30 | -91 | 44 | 107 |
| 31 Dec 17 | 19 | -66 | 29 | 81 |
| 31 Dec 16 | 20 | -29 | 5 | 57 |
| 31 Dec 15 | 17 | 20 | 4 | 33 |
| 30 Sep 14 | 10 | -9 | 4 | 20 |
Quality Earnings: 6YG is currently unprofitable.
Growing Profit Margin: 6YG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6YG is unprofitable, but has reduced losses over the past 5 years at a rate of 20.4% per year.
Accelerating Growth: Unable to compare 6YG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6YG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 6YG has a negative Return on Equity (-12.45%), as it is currently unprofitable.